88 related articles for article (PubMed ID: 9815807)
1. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.
Lamborn KR; DeNardo GL; DeNardo SJ; Goldstein DS; Shen S; Larkin EC; Kroger LA
Clin Cancer Res; 1997 Aug; 3(8):1253-60. PubMed ID: 9815807
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
3. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
[TBL] [Abstract][Full Text] [Related]
4. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.
DeNardo GL; Lamborn KR; DeNardo SJ; Goldstein DS; Dolber-Smith EG; Kroger LA; Larkin EC; Shen S
Cancer Res; 1995 Dec; 55(23 Suppl):5893s-5898s. PubMed ID: 7493366
[TBL] [Abstract][Full Text] [Related]
6. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
7. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
8. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; Lamborn KR; Goldstein DS; Kroger LA; DeNardo SJ
Cancer; 1997 Dec; 80(12 Suppl):2706-11. PubMed ID: 9406728
[TBL] [Abstract][Full Text] [Related]
9. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.
Shen S; DeNardo GL; Jones TD; Wilder RB; O'Donnell RT; DeNardo SJ
J Nucl Med; 1998 Jul; 39(7):1223-9. PubMed ID: 9669399
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
DeNardo GL; Kukis DL; Shen S; Mausner LF; Meares CF; Srivastava SC; Miers LA; DeNardo SJ
Clin Cancer Res; 1997 Jan; 3(1):71-9. PubMed ID: 9815540
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Kroger LA; DeNardo GL; Gumerlock PH; Xiong CY; Winthrop MD; Shi XB; Mack PC; Leshchinsky T; DeNardo SJ
Cancer Biother Radiopharm; 2001 Jun; 16(3):213-25. PubMed ID: 11471486
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
13. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1.
De Nardo GL; Kroger LA; Mirick GR; Lamborn KR; De Nardo SJ
Int J Biol Markers; 1995; 10(2):67-74. PubMed ID: 7561241
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
DeNardo SJ; Kroger LA; MacKenzie MR; Mirick GR; Shen S; DeNardo GL
Cancer Biother Radiopharm; 1998 Feb; 13(1):1-12. PubMed ID: 10850337
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
16. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL
Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.
Shen S; DeNardo GL; DeNardo SJ; Salako Q; Morris G; Banks D; Yuan A; DeNardo DA
J Nucl Med; 1996 Jan; 37(1):146-50. PubMed ID: 8543984
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of lymphoma: a UC Davis experience.
Lewis JP; Denardo GL; Denardo SJ
Hybridoma; 1995 Apr; 14(2):115-20. PubMed ID: 7590765
[TBL] [Abstract][Full Text] [Related]
19. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
